Pembrolizumab Disease-Free Survival Persists Long Term in RCC
Updated data from the KEYNOTE-564 trial shows pembrolizumab disease-free survival persists long...
Read More
Meeting Coverage
Good Response With Nivolumab Plus Axitinib in Metastatic RCC
Combination treatment with nivolumab plus axitinib has achieved a high response rate in...
Read More
Biomarkers Predict Response to Immune Nivolumab (± Ipilimumab) in Advanced RCC
Biomarker analysis of the phase 2 TITAN-RCC trial identified specific immune cell-related...
Read More
Avelumab Plus Axitinib May Benefit High-Risk Early RCC
Results of the NeoAvAx trial indicate that the neoadjuvant combination of avelumab plus axitinib...
Read MoreHealth and Safety at ASCO GU 2022
Individual Accountability ASCO is committed to maintaining the health and safety of all ASCO Genitourinary Cancers Symposium attendees. We will be reviewing the latest Centers for Disease Control and Prevention and World Health...
Read MoreActive Surveillance Helps Delay Systemic Therapy in Some With Metastatic Renal Cell Carcinoma
Active surveillance (AS) may be used effectively in a subgroup of patients(pts) with metastatic renal cell carcinoma (RCC) and indolent disease to postpone the commencement of systemic treatment without affecting long-term...
Read MoreMindfulness App Helps Address Psychosocial Distress in Patients With Metastatic Renal Cell Carcinoma
mRCC was linked to a high incidence of distress, a high degree of symptom load, and a wide range of quality-of-life impairments. A smartphone application aimed at enhancing mindfulness has been developed from a Mindfulness-Based...
Read MoreTele-mentoring Benefits Patients With Renal Cell Carcinoma
In recent years, the overall survival from metastatic renal cell carcinoma (RCC) has improved, mainly in part due to immune checkpoint inhibitors (ICI) and tyrosine kinase inhibitors (TKI). TKI and ICI had distinct and...
Read MoreResponse to Lenvatinib + Pembrolizumab in Advanced Renal Cell Carcinoma Regardless of Biomarker Status
Lenvatinib (lenva) + pembrolizumab (pembro) demonstrated encouraging antitumor activity and controllable safety characteristics in treatment-naive (n=23) or earlier cured metastatic RCC (n=105, initially medicated with immune...
Read MoreASCO GU Program Guide 2022
Thursday, Feb 17: Exhibits Open 10:00 AM – 9:45 PM EST Novel Treatment Implementation: Prostate-Specific Membrane Antigen Targeting and Beyond Primary Track: Prostate Cancer 10:45 AM – 12:30 PM EST Optimizing Management of...
Read MoreASCO GU 2022 Is Here!
Program at a Glance • Highly interactive sessions with multidisciplinary perspectives on new, innovative findings in the study, diagnosis, and treatment of GU malignancies. • Presentation of the latest novel science and...
Read More
ASH 2021: A Focus on Leukemia & Lymphoma
Focus on Lymphoma Leukemia
Read More
Take Our ASOPRS Quiz!
The ASOPRS 2022 PhysQuiz was created by the editorial staff at Physician’s Weekly. The ASOPRS 2022...
Read MorePatients With Non-Hodgkin’s Lymphoma Subtypes Incur High Hospital Costs
According to published data, patients with mantle cell lymphoma (MCL), Waldenström macroglobulinemia (WM), marginal zone lymphoma (MZL), and chronic lymphocytic leukemia (CLL) experience frequent relapses over the course of...
Read MoreVenetoclax/Idelalisib Regimens Better Option After First-Line Ibrutinib for CLL/SLL
The establishment of ibrutinib as a preferred first-line treatment option makes it important to understand the treatment sequence following first-line ibrutinib and the patient characteristics of those treated with a second-line...
Read MoreDelayed Start of Therapy Feasible in Some Patients With MCL
Currently, the effect of the diagnosis-to-treatment interval (DTI) on survival in patients with mantle cell lymphoma (MCL) has not been extensively examined. Researchers aimed to determine the feasibility of active surveillance...
Read MoreAddition of Ibrutinib to Chemoimmunotherapy in CLL
The combination of fludarabine, cyclophosphamide, and rituximab (FCR) is the only regimen other than allotransplantation shown in studies to result in a significant chance of functional cure in very long-term follow-up for...
Read More
Guidelines For Paediatric Clinical Practice Of High Quality
Pediatric clinical practice guidelines (CPGs) have lacked a full review in recent years....
Read More
ASOPRS 2021: A Focus on Thyroid Eye Disease eBook
Focus on Thyroid Eye Disease eBook
Read More